Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for ...
IPWatchdog

PTAB Upholds Priority Win for Broad Institute in CRISPR Patent Case

On remand from the Federal Circuit, the Patent Trial and Appeal Board on Thursday reaffirmed its decision that The Broad ...

Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

Parliament panel seeks 100% MSP procurement for oilseeds, pulses

A standing committee of Parliament on Agriculture has called for 100 per cent procurement of oilseeds and pulses at the minimum support price (MSP), as against the current 25 per cent, to bring down ...
The Caledonian-Record

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the ...

Parliamentary panel seeks seed price regulator, new Seeds Bill

A parliamentary panel has recommended setting up a regulatory body to fix seed prices in India, stressed the urgent need for ...
Medindia

In Vivo Gene Editing: A New Frontier in Cancer Immunotherapy

A new technique may reprogram immune cells inside the body, offering faster, simpler, and more accessible cancer treatment.